<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03127202</url>
  </required_header>
  <id_info>
    <org_study_id>RTSY01</org_study_id>
    <nct_id>NCT03127202</nct_id>
  </id_info>
  <brief_title>Left Ventricular Pacing Vectors Effectiveness to Narrow Phrenic Nerve Stimulation</brief_title>
  <acronym>ORPHEE</acronym>
  <official_title>Evaluation of Left Ventricular Pacing Vectors Use in Phrenic Nerve Stimulation Management and Left Ventricular Parameters Adjustment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LivaNova</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LivaNova</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of three left ventricular pacing polarities effectiveness to narrow phrenic nerve
      stimulation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary endpoint of the study aims at demonstrating that the three left ventricular
      polarities in the Cardiac Resynchronisation Therapy-Defibrillator could bypass phrenic nerve
      stimulation at least in 90% of implants.

      Success was defined as an absence of phrenic nerve stimulation (threshold &gt; 7V) or in case of
      phrenic nerve stimulation occurrence (threshold &lt; 7V), as the resolution of the phrenic nerve
      stimulation by reprogramming one of the 3 left ventricular pacing polarities available in the
      device : left ventricular tip- left ventricular ring (bipolar), left ventricular tip- right
      ventricular ring (pseudo-bipolar) and left ventricular ring-right ventricular coil.

      Any occurrence of phrenic nerve stimulation without resolution by reprogramming was
      considered as a failure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phrenic nerve stimulation measurement</measure>
    <time_frame>The presence of phrenic nerve stimulation will be assessed at implant.</time_frame>
    <description>The presence of phrenic nerve stimulation at 10 Volt, using a pacing system analyzer</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Cardiac Resynchronization Therapy-Defibrillator</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients were implanted with a Cardiac Resynchronization Therapy -Defibrillator</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardiac Resynchronization Therapy -Defibrillator (range PARADYM, LivaNova, Clamart, France)</intervention_name>
    <description>Patients were implanted with a Cardiac Resynchronization Therapy -Defibrillator (model PARADYM RF SONR CRT-D 9770 or PARADYM RF CRT-D 9750, Sorin) having 3 left ventricular polarities. The choice of the right atrial, right ventricular and bipolar left ventricular leads was left to investigators' discretion.</description>
    <arm_group_label>Cardiac Resynchronization Therapy-Defibrillator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible for an implantation of a Cardiac Resynchronization Therapy-Defibrillator
             according to relevant regulations (will be only tolerated primo-implantation and
             upgrade)

          -  Patient scheduled for implantation of a Cardiac Resynchronization
             Therapy-Defibrillator

          -  Patient has given his informed consent

        Exclusion Criteria:

          -  Any contraindication for Implantable Cardioverter Defibrillator therapy

          -  Heart transplantation or waiting for heart transplantation

          -  Implanted with a ventricular assist device (VAD)

          -  Inability to understand the purpose of the study or to cooperate

          -  Not available for routine follow-up visits

          -  Life expectancy less than 12 months

          -  Age of less than 18 years and et pregnancy

          -  Under guardianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henri BENKEMOUN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Saint Pierre - Perpignan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CH Annecy</name>
      <address>
        <city>Annecy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Mondor</name>
      <address>
        <city>Cr√©teil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH LENS</name>
      <address>
        <city>Lens</city>
        <zip>62307</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Bretagne Sud</name>
      <address>
        <city>Lorient</city>
        <zip>56322</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Clairval</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHP Beauregard</name>
      <address>
        <city>Marseille</city>
        <zip>13012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique de Gentilly</name>
      <address>
        <city>Nancy</city>
        <zip>54100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Groupe Hospitalo-universitaire Caremeau</name>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de La Source</name>
      <address>
        <city>Orleans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH St Joseph</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique St Pierre</name>
      <address>
        <city>Perpignan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2016</study_first_submitted>
  <study_first_submitted_qc>April 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2017</study_first_posted>
  <last_update_submitted>April 24, 2017</last_update_submitted>
  <last_update_submitted_qc>April 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiac Resynchronization Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

